Navigation Links
Cerecor Acquires Rights to NR2B Receptor Antagonist from Merck
Date:4/19/2013

BALTIMORE, April 19, 2013 /PRNewswire/ -- Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

There is a growing body of evidence to support the hypothesis that NMDA receptors are involved in the pathology of depression, including reports in the literature of rapid improvement of depression following intravenous administration of ketamine, an NMDA antagonist. MK-0657 is a novel potent and selective NR2B antagonist, initially developed by Merck for the treatment of Parkinson's disease.

"MK-0657 is a potential first-in-class, best-in-class, oral medication that is complementary to existing treatments in depressed patients who have failed to respond to available therapies. We are particularly interested in the potential to rapidly reduce depressive symptoms, including suicidal ideation, in these severely affected patients," stated Dr. James Vornov , Cerecor's Sr. VP of Clinical Development and Regulatory Affairs.

Under the terms of the agreement, Cerecor will immediately assume full development and commercialization responsibilities of MK-0657.  License consideration includes milestone payments and royalties consistent with clinical stage licenses in neuroscience. Cerecor anticipates completing the technology transfer activities by mid-2013 and thereafter initiating clinical trials.

"We are delighted that Merck has chosen Cerecor to help realize the value of an innovative asset such as MK-0657," added Dr. Blake Paterson , Cerecor's co-founder and CEO. "Patients and families who have struggled with severe refractory depression and suicidality easily recognize the need for more effective treatments, and we will develop MK-0657 with the purpose that befits such an important unmet need."

"Merck is pleased to sign this agreement with Cerecor as part of its ongoing out-licensing strategy.  Cerecor has established scientific and clinical expertise in the area of treatment resistant depression, an area of significant unmet medical need," said Dr. David Michelson , Vice President of Clinical Neuroscience and Ophthalmology, Merck Research Laboratories.

About Cerecor

Cerecor Inc is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We focus on targets or technologies that have demonstrated human proof of concept, and for which biomarkers could be used to steer early clinical development.  We are a Delaware corporation, based in Baltimore and co-founded in April 2011 by Drs. Solomon Snyder , Barbara Slusher , Blake Paterson and Mr. Isaac Blech .  Cerecor is focused on translational medicine – the accelerated transfer of technology from the laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.  www.cerecor.com

Media Contact:
Michelle Avery
MacDougall Biomedical Communications
781-235-3060


'/>"/>
SOURCE Cerecor Inc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerecor Acquires Rights to Merck COMT Inhibitors
2. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
3. Dr. Magnus Persson Joins Cerecors Board of Directors
4. Cerecor Announces Initiation of CLIN01-002-A
5. MD Anderson Cancer Center Acquires Two Elekta Versa HD Systems
6. Numotion Acquires Ultimate Mobility, Inc.
7. VWR International, LLC Acquires Basan UK Limited
8. Kimberly-Clark Health Care Acquires Anesthesia Business from Life-Tech
9. VWR International, LLC Acquires Prolab Laboratuar Teknolojileri Limited In Turkey
10. Oncologix Tech Inc. (OCLG) Acquires Dotolo; Gains Ongoing Sales, Patents, and New CEO
11. Kimberly-Clark Heath Care Acquires Anesthesia Business from Life-Tech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... -- On Thursday, February 16, 2017, the ... the closing bell, while the Dow Jones Industrial Average ... five out of nine sectors ended Thursday,s trading session ... Stock-Callers.com assessed the following Medical Appliances & Equipment equities ... SNN ), ABIOMED Inc. (NASDAQ: ABMD ), ...
(Date:2/16/2017)... EXTON, Pa. , Feb. 16, 2017 ... drugs, biologics, and medical devices, is pleased to announce ... Ph.D., has been selected as a winner of the ... SmartCEO Magazine and recognizes driven executives for ... undeniable work ethic. The awards ceremony and celebration is ...
(Date:2/16/2017)... , Feb. 16, 2017 Quest Diagnostics (NYSE: ... diagnostic information services, today announced that it has been ... 2017 by Fortune. The annual survey ... in the "Health Care: Pharmacy and Other Services" industry ... information services company to attain the designation. This is ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, ... Pet Life Radio network. The episode, which was posted this week, features a ... factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association of ...
(Date:2/17/2017)... NC (PRWEB) , ... February 17, 2017 , ... Smiles ... Commons Shopping Center in Davidson, NC. Dr. Brian Seese leads the practice as a ... dental services under one roof. Smiles by Seese serves patients of all ages with ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers ... of controlled and non-controlled substances plus the ability to manage orders on their ... States now accept electronic prescriptions, according to the Office of the National Coordinator ...
(Date:2/17/2017)... Palos Verdes, CA (PRWEB) , ... February 17, ... ... and emotional flow is Dr. Carol Francis' goals for each and ... Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which help ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s ... most widely used electronic patient signatures solution in healthcare . , ...
Breaking Medicine News(10 mins):